Results 101 to 110 of about 1,580 (184)

French‐Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Clinical Use of Mavacamten

International audienceMavacamten, the first drug in the class of β‐cardiac myosin modulator, is used for the treatment of patients with hypertrophic cardiomyopathy.
Laffitte‐redondo, Clara, Gautier-Veyret, Elodie, Ait Tayeb, Abd El Kader, Ayme-Dietrich, Estelle, Vilquin, Paul, Picard, Nicolas, Haufroid, Vincent, Hennart, Benjamin, Lafay-Chebassier, Claire, Médard, Yves, Boyer, Jean-Christophe, Evrard, Alexandre, Ayme‐dietrich, Estelle, Baklouti, Sarah, Davaze-Schneider, Julie, Lamoureux, Fabien, Gautier‐veyret, Elodie, Ben-Sassi, Mouna, Verstuyft, Céline, Cunat, Séverine, Wils, Julien, French‐Speaking Network of Pharmacogenetics (RNPGx), Lebreton, Louis, Laffitte-Redondo, Clara, Quaranta, Sylvie   +24 more
core   +1 more source

Forest plot showing changes in NT-proBNP of Mavacamten group compared to placebo at random effect.

Forest plot showing changes in NT-proBNP of Mavacamten group compared to placebo at random effect.
Kalgi Modi (7699319), Mansunderbir Singh (18405132), Anuj Thakre (18405138), Sahith Reddy Thotamgari (15947040), Rahul Vyas (18405123), Shubhika Jain (17719146), Viraj Panchal (18405126), Keerthish Jaisingh (18405135), Manush Sondhi (18405129)   +8 more
core   +1 more source

Forest plot showing KCCQ-CSS score of the Mavacamten group compared to placebo at random effect.

Forest plot showing KCCQ-CSS score of the Mavacamten group compared to placebo at random effect.
Kalgi Modi (7699319), Mansunderbir Singh (18405132), Anuj Thakre (18405138), Sahith Reddy Thotamgari (15947040), Rahul Vyas (18405123), Shubhika Jain (17719146), Viraj Panchal (18405126), Keerthish Jaisingh (18405135), Manush Sondhi (18405129)   +8 more
core   +1 more source

Mavacamten toxicity, hepatic dysfunction, and rifampicin: cause or coincidence? [PDF]

Eur Heart J Case Rep
Mapelli M, Costantino S, Maragna R.
europepmc   +1 more source

Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: A Head-to-Head Network Meta-Analysis of Mavacamten and Aficamten

Background: Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterized by myocardial hypercontractility. Mavacamten and aficamten are first-in-class cardiac myosin inhibitors that have demonstrated efficacy in treating obstructive HCM. However,
Imran Saleh, Yenny Dian Andayani, Syamsu Indra, Rukiah Chodilawati, Yuniza   +4 more
core   +1 more source

Rifampicin for the treatment of a cardiogenic shock related to mavacamten toxicity: the worse and the best of drug interactions from a case report. [PDF]

Eur Heart J Case Rep
Lucas S, Hennart B, de Groote P, Lamblin N, Ridon H, Dupre C, Lionet A, Lemesle G.   +7 more
europepmc   +1 more source

Mavacamten inhibits myosin activity by stabilizing the myosin interacting-heads motif and stalling motor force generation. [PDF]

Sci Adv
McMillan SN, Pitts JRT, Barua B, Winkelmann DA, Scarff CA.   +4 more
europepmc   +1 more source

Correction to: Mavacamten: First Approval

Drugs, 2022
openaire   +1 more source

Cardiogenic shock and atrial fibrillation after mavacamten dose escalation in obstructive hypertrophic cardiomyopathy: a case report. [PDF]

Eur Heart J Case Rep
Jeong WJ, Kim SE, Cho SW, Namgung J, Ko KY.   +4 more
europepmc   +1 more source

Cardiac Myosin Inhibitors (CMIs) and Surgical Referral in Patients with Hypertrophic Cardiomyopathy. [PDF]

J Cardiovasc Dev Dis
Ferraresi B, Nenna A, Jawabra M, Corrado D, Faggiano A, Carugo S, Dominici C, Casali G, Chello M, Lusini M.   +9 more
europepmc   +1 more source